What did Northwest Pathology pay for Avero Diagnostics?

Northwest Pathology acquired Avero Diagnostics for $10.9M in 2021, equivalent to 0.20x revenue. Target revenue was approximately $69.5M.

What does Avero Diagnostics do?

Avero Diagnostics is a laboratory services business.

What multiple did Northwest Pathology pay for Avero Diagnostics?

0.20x revenue, based on disclosed deal value of $10.9M and disclosed financials.

M&A TRANSACTION · 2021

Avero Diagnostics acquired by Northwest Pathology

$10.9M· 0.20x revenue

Target

Avero Diagnostics

Acquirer

Northwest Pathology

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$69.5M

EBITDA

—

Deal Value

$10.9M

EV/EBITDA

—

Context

This $10.9M acquisition of Avero Diagnostics by Northwest Pathology sits in the laboratory services sub-vertical. Northwest Pathology is acquiring as a strategic buyer; see how strategic acquirers typically price laboratory services businesses on our Laboratory Services strategic buyer-pool page.

Source

Data sourced from SEC filings. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own laboratory services

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the Avero Diagnostics acquisition.

Citation: ExitValue.ai. (2021). Avero Diagnostics acquired by Northwest Pathology. https://exitvalue.ai/deals/avero-diagnostics-acquired-by-northwest-pathology-hc-2021-0079